Qurient Co Ltd (115180):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Qurient Co Ltd (115180) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8265
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Qurient Co Ltd (Qurient) is a pharmaceutical company that offers development of new drugs for unmet medical needs. The company provides portfolio of pipeline products such as Q301, Q203, Q701, 5LO INH and CDK7 INH, among others. It is developing products for the treatment of atopic dermatitis; extensively drug-resistant tuberculosis (XDR) and multi drug resistant (MDR) and totally drug resistant (TDR) tuberculosis (TB); asthama and cancer, among others. Qurient works in partnership with research institutes, CRO and research hospitals for development of new therapeutics. The company offers services in partnership of CMO for research and development of new therapeutics. Qurient is headquartered in Seongnam, South Korea.

Qurient Co Ltd (115180) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Qurient Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Qurient Raises USD15.5 Million in Series F Venture Financing 10
Qurient Raises USD3 Million in Series E Venture Financing 12
Qurient Raises US$4 Million In Venture Financing 13
Partnerships 14
Qurient Enters into Agreement with Lead Discovery Center 14
Licensing Agreements 15
Lead Discovery Center Enters into Licensing Agreement with Qurient 15
Qurient Enters Into Licensing Agreement with Max Planck Society and Lead Discovery Center 16
Infectex Enters Into Licensing Agreement With Qurient For Tuberculosis Drug Q203 17
Max Planck Institute of Biochemistry And Lead Discovery Center Enter Into Licensing Agreement With Qurient For Kinase Inhibitor 18
Equity Offering 20
Qurient Raises USD25.7 Million in IPO 20
Qurient Co Ltd – Key Competitors 21
Qurient Co Ltd – Key Employees 22
Qurient Co Ltd – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Clinical Trials 24
Jun 22, 2017: Infectex Successfully Completes Phase 1 Clinical Study of Q203 for Treatment of Tuberculosis 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Qurient Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Qurient Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Qurient Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Qurient Raises USD15.5 Million in Series F Venture Financing 10
Qurient Raises USD3 Million in Series E Venture Financing 12
Qurient Raises US$4 Million In Venture Financing 13
Qurient Enters into Agreement with Lead Discovery Center 14
Lead Discovery Center Enters into Licensing Agreement with Qurient 15
Qurient Enters Into Licensing Agreement with Max Planck Society and Lead Discovery Center 16
Infectex Enters Into Licensing Agreement With Qurient For Tuberculosis Drug Q203 17
Max Planck Institute of Biochemistry And Lead Discovery Center Enter Into Licensing Agreement With Qurient For Kinase Inhibitor 18
Qurient Raises USD25.7 Million in IPO 20
Qurient Co Ltd, Key Competitors 21
Qurient Co Ltd, Key Employees 22

List of Figures
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Qurient Co Ltd (115180):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Alabama Municipal Electric Authority:企業の戦略的SWOT分析
    Alabama Municipal Electric Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • YRC Worldwide Inc (YRCW):企業の財務・戦略的SWOT分析
    YRC Worldwide Inc (YRCW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Aptiv Plc:企業の戦略・SWOT・財務分析
    Aptiv Plc - Strategy, SWOT and Corporate Finance Report Summary Aptiv Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Celtaxsys Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Celtaxsys Inc (Celtaxsys) is a clinical-stage pharmaceutical development company that develops novel foundational therapies to treat inflammation in rare, orphan designated diseases. Oral once daily acebilustat, the company’s flagship drug candidate under phase 2 clinical trial, is intended …
  • ABC arbitrage SA (ABCA):企業の財務・戦略的SWOT分析
    ABC arbitrage SA (ABCA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Kyushu Financial Group Inc (7180):企業の財務・戦略的SWOT分析
    Kyushu Financial Group Inc (7180) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Acadia Pharmaceuticals Inc (ACAD)-製薬・医療分野:企業M&A・提携分析
    Summary Acadia Pharmaceuticals Inc (Acadia) discovers, develops and commercializes small molecule drugs for the treatment of central nervous system disorders. The company’s lead product Nuplazid (pimavanserin) is an FDA approved drug for the treatment of Parkinson’s disease psychosis. Acadia also de …
  • QEP Resources Inc (QEP):石油・ガス:M&Aディール及び事業提携情報
    Summary QEP Resources Inc (QEP) is an independent oil and natural gas exploration and production company. It has operating interests in Northern Region chiefly in North Dakota, Wyoming and Utah; and Southern Region essentially in Texas and Louisiana. In Northern Region, the company owns productive w …
  • Companhia Energetica de Minas Gerais SA (CMIG4):企業の財務・戦略的SWOT分析
    Companhia Energetica de Minas Gerais SA (CMIG4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • Systematic A/S:企業の戦略・SWOT・財務情報
    Systematic A/S - Strategy, SWOT and Corporate Finance Report Summary Systematic A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • TyraTech Inc (TYR):企業の財務・戦略的SWOT分析
    Summary TyraTech Inc (TyraTech) is a clean technology and life science company that manufactures, markets, and develops insect and parasite control products. The company offers products such as equine fly spray, head lice solutions, insect repellent, insect and parasite products, and production anim …
  • AU Optronics Corp.:企業の戦略・SWOT・財務情報
    AU Optronics Corp. - Strategy, SWOT and Corporate Finance Report Summary AU Optronics Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • PulteGroup Inc (PHM):企業の財務・戦略的SWOT分析
    PulteGroup Inc (PHM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Hoegh LNG Holdings Ltd (HLNG):企業の財務・戦略的SWOT分析
    Summary Hoegh LNG Holdings Ltd (Hoegh LNG), formerly known as Leif Hoegh & Co Ltd is an oil and gas company that offers floating energy solutions. The company's services include floating storage and regasification unit solutions, in-house ship management, floating LNG energy services, LNG regasifica …
  • HSBC Seguros de Vida Argentina S.A.:企業の戦略・SWOT・財務情報
    HSBC Seguros de Vida Argentina S.A. - Strategy, SWOT and Corporate Finance Report Summary HSBC Seguros de Vida Argentina S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • e-Therapeutics Plc (ETX):企業の財務・戦略的SWOT分析
    e-Therapeutics Plc (ETX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • BRT Apartments Corp.:企業の戦略・SWOT・財務情報
    BRT Apartments Corp. - Strategy, SWOT and Corporate Finance Report Summary BRT Apartments Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Arkansas Electric Cooperative Corporation:発電所・企業SWOT分析
    Arkansas Electric Cooperative Corporation - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, inform …
  • Qatar Electricity & Water Company QSC:発電所・企業SWOT分析
    Qatar Electricity & Water Company QSC - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informatio …
  • Axelar AB-製薬・医療分野:企業M&A・提携分析
    Summary Axelar AB (Axelar) is a drug development company that develops various novel anti-cancer treatments. The company develops AXL1717, a novel anti cancer compound that inhibits tumor growth and reduces tumor sizes of malignant cells such as prostate cancer, breast cancer, glioblastoma, sarcoma, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆